Phaseline

Companies › Shandong Suncadia Medicine

Shandong Suncadia Medicine: clinical trials, targets and expected readouts

19 active drug programs in 40 registered trials: 18 Phase 2, 15 Phase 1, 7 Phase 3; Oncology, Cardiovascular, Metabolic and endocrine, Immunology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HRS-1780 Tablets
Aldosterone synthase inhibitor
–Phase 3Chronic Kidney Disease; Primary Aldosteronism; Uncontrolled or Resistant HypertensionNov 2026
HRS-1893
Cardiac myosin inhibitor
–Phase 3Obstructive Hypertrophic Cardiomyopathy; Heart Failure With Preserved Ejection Fraction; Hypertrophic CardiomyopathyNov 2026
HRS-7535–Phase 3Hypertension With Overweight or Obesity; Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and ObesityDec 2026
HRS-8080
CDK4/6 inhibitor
CDK4, CDK6Phase 3Locally Advanced Breast Cancer; Locally Advanced or Metastatic Breast Cancer; Breast Cancer; Unresectable or Metastatic Breast Cancer …Dec 2026
HRS-2129–Phase 2Postoperative Analgesia; Acute Gouty Arthritis; Diabetic Peripheral Neuropathic PainNov 2026
Bevacizumab (BP102)
Vascular endothelial growth factor A inhibitor
VEGFAPhase 2Advanced Malignant TumourDec 2026
HRS-7058
KRAS G12C selective inhibitor
KRASPhase 2Advanced Malignant Tumour; Solid Tumors; Pancreatic CancerDec 2026
HRS-7085–Phase 2Adult Patients With Moderately to Severely Active Ulcerative ColitisDec 2026
SHR-1826–Phase 2Advanced Malignant TumourDec 2026
SHR-9839–Phase 2Advanced Malignant TumourDec 2026
SHR-A1202–Phase 2Advanced Malignant TumourDec 2026
HRS-1301–Phase 2Hyperlipidemia–
HRS-1358–Phase 1Advanced Unresectable or Metastatic Breast CancerDec 2026
HRS-2189–Phase 1Advanced Unresectable or Metastatic Breast CancerDec 2026
HRS-6209–Phase 1Advanced Unresectable or Metastatic Breast Cancer; Advanced Unresectable or Metastatic Breast Cancer of AdultsDec 2026
HRS-6208–Phase 1Solid Tumors; Advanced Unresectable or Metastatic Breast Cancer of AdultsAug 2027
HRS-6719
MTAP inhibitor
–Phase 1Advanced/Metastatic Solid TumorsDec 2027
HRS-3802–Phase 1Advanced Solid TumorsDec 2028
HRS-7156–Phase 1Heart Failure–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06516068HRS-1893Phase 2Obstructive Hypertrophic CardiomyopathyCardiovascularNov 2024
NCT07185594HRS-2129Phase 2Postoperative AnalgesiaOtherDec 2025
NCT06167694HRS-8080Phase 1Unresectable or Metastatic Breast CancerOncologyJun 2026
NCT06167694HRS-8080Phase 1Unresectable or Metastatic Breast CancerOncologyJun 2026
NCT06383871HRS-7058Phase 1Advanced Malignant TumourOncologyJun 2026
NCT07229937HRS-1301Phase 2HyperlipidemiaMetabolic and endocrineAug 2026
NCT07601087HRS-7156Phase 1Heart FailureCardiovascularSep 2026
NCT07470983HRS-1780 TabletsPhase 2Primary AldosteronismMetabolic and endocrineNov 2026
NCT07021976HRS-1893Phase 3Obstructive Hypertrophic CardiomyopathyCardiovascularNov 2026
NCT07706777HRS-2129Phase 2Acute Gouty ArthritisImmunologyNov 2026
NCT07377721HRS-2129Phase 1Diabetic Peripheral Neuropathic PainNeurologyNov 2026
NCT06820099HRS-7535Phase 2Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and ObesityCardiovascularDec 2026
NCT06915142HRS-7058Phase 2Advanced Malignant TumourOncologyDec 2026
NCT07229950HRS-7085Phase 2Adult Patients With Moderately to Severely Active Ulcerative ColitisImmunologyDec 2026
NCT06915142SHR-1826Phase 2Advanced Malignant TumourOncologyDec 2026
NCT06915142SHR-A1202Phase 2Advanced Malignant TumourOncologyDec 2026
NCT06915142Bevacizumab (BP102)Phase 2Advanced Malignant TumourOncologyDec 2026
NCT06915142SHR-9839Phase 2Advanced Malignant TumourOncologyDec 2026
NCT06679036HRS-2189Phase 1Advanced Unresectable or Metastatic Breast CancerOncologyDec 2026
NCT06679036HRS-8080Phase 1Advanced Unresectable or Metastatic Breast CancerOncologyDec 2026
NCT06679036HRS-6209Phase 1Advanced Unresectable or Metastatic Breast CancerOncologyDec 2026
NCT06679036HRS-1358Phase 1Advanced Unresectable or Metastatic Breast CancerOncologyDec 2026
NCT07269717HRS-1893Phase 2Heart Failure With Preserved Ejection FractionCardiovascularMar 2027
NCT07032077HRS-7058Phase 2Solid TumorsOncologyJun 2027
NCT07024173HRS-8080Phase 3Locally Advanced Breast CancerOncologyAug 2027
NCT06727812HRS-6208Phase 1Solid TumorsOncologyAug 2027
NCT07125950HRS-8080Phase 2Advanced Breast CancerOncologySep 2027
NCT07528027HRS-7535Phase 3Hypertension With Overweight or ObesityCardiovascularDec 2027
NCT07021963HRS-1893Phase 2Hypertrophic CardiomyopathyCardiovascularDec 2027
NCT06922357HRS-6719Phase 1Advanced/Metastatic Solid TumorsOncologyDec 2027
NCT07354022HRS-8080Phase 3Locally Advanced or Metastatic Breast CancerOncologyDec 2028
NCT07354022HRS-8080Phase 3Locally Advanced or Metastatic Breast CancerOncologyDec 2028
NCT07389733HRS-8080Phase 1Advanced Unresectable or Metastatic Breast Cancer of AdultsOncologyDec 2028
NCT07389733HRS-6209Phase 1Advanced Unresectable or Metastatic Breast Cancer of AdultsOncologyDec 2028
NCT07389733HRS-6208Phase 1Advanced Unresectable or Metastatic Breast Cancer of AdultsOncologyDec 2028
NCT06770569HRS-3802Phase 1Advanced Solid TumorsOncologyDec 2028
NCT07589569HRS-7058Phase 2Pancreatic CancerOncologyDec 2028
NCT07708441HRS-1780 TabletsPhase 2Uncontrolled or Resistant HypertensionCardiovascularApr 2029
NCT07419828HRS-1780 TabletsPhase 3Chronic Kidney DiseaseGenitourinaryApr 2030
NCT07349069HRS-8080Phase 3Breast CancerOncologyDec 2030

Targets

CDK4 (1) CDK6 (1) KRAS (1) VEGFA (1)

Companies with the same targets

Roche Pfizer Eli Lilly Revolution Medicines Jiangsu HengRui Medicine Novartis Jiangsu Simcere Pharmaceutical Chia Tai Tianqing Pharmaceutical Group AstraZeneca TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Companies built like this

Shanghai Hengrui Pharmaceutical Jiangsu Simcere Pharmaceutical Shanghai Henlius Biotech Akeso Sichuan Baili Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.